ondansetron has been researched along with Constipation in 10 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Constipation: Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this phase III trial was to evaluate the efficacy and safety of regimens containing casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting during the first cycle in patients receiving moderately emetogenic chemotherapy (MEC)." | 9.14 | Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. ( Apornwirat, W; Aziz, Z; Grunberg, SM; Guckert, M; Herrstedt, J; Levin, J; Ranganathan, S; Roila, F; Russo, MW; Shaharyar, A; Van Belle, S, 2009) |
| "The effect of a single intravenous dose of ondansetron in preventing postoperative nausea and emesis (retching and vomiting) (PONV) was investigated in a randomized, double-blind, placebo-controlled, multicentre, international study." | 9.07 | A single i.v. dose of ondansetron 8 mg prior to induction of anaesthesia reduces postoperative nausea and vomiting in gynaecological patients. ( Abrahamsson, J; Briggs, L; Forrler, M; Hellstern, K; Helmers, JH; Moodley, J; Soni, J, 1993) |
| "The effect of three times daily oral ondansetron in preventing postoperative nausea and vomiting was investigated in two randomized, double-blind, placebo-controlled, multi-centre studies." | 9.07 | Oral ondansetron in the prevention of postoperative nausea and vomiting. ( Helmers, JH, 1992) |
| "Fatigue is common in primary biliary cirrhosis (PBC)." | 6.71 | A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. ( Burak, KW; Girlan, L; Heathcote, EJ; Heslegrave, RJ; Huet, PM; Swain, M; Theal, JJ; Tomlinson, GA; Toosi, MN, 2005) |
| "The purpose of this phase III trial was to evaluate the efficacy and safety of regimens containing casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting during the first cycle in patients receiving moderately emetogenic chemotherapy (MEC)." | 5.14 | Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. ( Apornwirat, W; Aziz, Z; Grunberg, SM; Guckert, M; Herrstedt, J; Levin, J; Ranganathan, S; Roila, F; Russo, MW; Shaharyar, A; Van Belle, S, 2009) |
| "Compared with ondansetron alone, the casopitant and ondansetron combination results in superior emesis prevention during the first 24 h postoperatively in female patients with known risk factors for postoperative nausea and vomiting." | 5.14 | Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients. ( Blackburn, L; Chung, F; Johnson, B; Kutsogiannis, DJ; Lane, SR; Levin, J; Pergolizzi, JV; Singla, NK; Singla, SK, 2010) |
| "The effect of a single intravenous dose of ondansetron in preventing postoperative nausea and emesis (retching and vomiting) (PONV) was investigated in a randomized, double-blind, placebo-controlled, multicentre, international study." | 5.07 | A single i.v. dose of ondansetron 8 mg prior to induction of anaesthesia reduces postoperative nausea and vomiting in gynaecological patients. ( Abrahamsson, J; Briggs, L; Forrler, M; Hellstern, K; Helmers, JH; Moodley, J; Soni, J, 1993) |
| "The effect of three times daily oral ondansetron in preventing postoperative nausea and vomiting was investigated in two randomized, double-blind, placebo-controlled, multi-centre studies." | 5.07 | Oral ondansetron in the prevention of postoperative nausea and vomiting. ( Helmers, JH, 1992) |
| "Fatigue is common in primary biliary cirrhosis (PBC)." | 2.71 | A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. ( Burak, KW; Girlan, L; Heathcote, EJ; Heslegrave, RJ; Huet, PM; Swain, M; Theal, JJ; Tomlinson, GA; Toosi, MN, 2005) |
| "Nausea was absent or mild in 79% of patients on day 1, 45% on day 2 and 41% on day 3." | 2.68 | A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation. ( Barbounis, V; Efremidis, AP; Hatzichristou, H; Koumakis, G; Tsousis, S; Vassilomanolakis, M, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kishi, T | 1 |
| Mukai, T | 1 |
| Matsuda, Y | 1 |
| Iwata, N | 1 |
| Herrstedt, J | 1 |
| Apornwirat, W | 1 |
| Shaharyar, A | 1 |
| Aziz, Z | 1 |
| Roila, F | 1 |
| Van Belle, S | 1 |
| Russo, MW | 1 |
| Levin, J | 2 |
| Ranganathan, S | 1 |
| Guckert, M | 1 |
| Grunberg, SM | 1 |
| Singla, NK | 1 |
| Singla, SK | 1 |
| Chung, F | 1 |
| Kutsogiannis, DJ | 1 |
| Blackburn, L | 1 |
| Lane, SR | 1 |
| Johnson, B | 1 |
| Pergolizzi, JV | 1 |
| Hayashi, T | 1 |
| Ikesue, H | 1 |
| Esaki, T | 1 |
| Fukazawa, M | 1 |
| Abe, M | 1 |
| Ohno, S | 1 |
| Tomizawa, T | 1 |
| Oishi, R | 1 |
| Theal, JJ | 1 |
| Toosi, MN | 1 |
| Girlan, L | 1 |
| Heslegrave, RJ | 1 |
| Huet, PM | 1 |
| Burak, KW | 1 |
| Swain, M | 1 |
| Tomlinson, GA | 1 |
| Heathcote, EJ | 1 |
| Wilkes, G | 1 |
| Helmers, JH | 2 |
| Briggs, L | 1 |
| Abrahamsson, J | 1 |
| Soni, J | 1 |
| Moodley, J | 1 |
| Forrler, M | 1 |
| Hellstern, K | 1 |
| Barbounis, V | 1 |
| Koumakis, G | 1 |
| Vassilomanolakis, M | 1 |
| Hatzichristou, H | 1 |
| Tsousis, S | 1 |
| Efremidis, AP | 1 |
| McCune, JS | 1 |
| Oertel, MD | 1 |
| Pfeifer, D | 1 |
| Houston, SA | 1 |
| Bingham, A | 1 |
| Sawyer, WT | 1 |
| Lindley, CM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist Casopitant (GW679769) in Combination With Ondansetron a[NCT00366834] | Phase 3 | 1,840 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antagonist, GW679769, When Administered With Intravenous Ondan[NCT00108095] | Phase 2 | 701 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ondansetron and Constipation
| Article | Year |
|---|---|
Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review.
Topics: Antipsychotic Agents; Constipation; Double-Blind Method; Drug Therapy, Combination; Granisetron; Hal | 2014 |
6 trials available for ondansetron and Constipation
| Article | Year |
|---|---|
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Topics: Administration, Oral; Alopecia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2009 |
Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients.
Topics: Administration, Oral; Adolescent; Adult; Anesthesia, General; Antiemetics; Cholecystectomy, Laparosc | 2010 |
A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue.
Topics: Constipation; Cross-Over Studies; Fatigue; Headache; Humans; Liver Cirrhosis, Biliary; Middle Aged; | 2005 |
A single i.v. dose of ondansetron 8 mg prior to induction of anaesthesia reduces postoperative nausea and vomiting in gynaecological patients.
Topics: Adolescent; Adult; Aged; Anesthesia, General; Bradycardia; Constipation; Double-Blind Method; Female | 1993 |
A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Constipation; Female | 1995 |
Oral ondansetron in the prevention of postoperative nausea and vomiting.
Topics: Administration, Oral; Adult; Alanine Transaminase; Aspartate Aminotransferases; Constipation; Double | 1992 |
3 other studies available for ondansetron and Constipation
| Article | Year |
|---|---|
Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation.
Topics: Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2012 |
Antiemetic agents.
Topics: Administration, Oral; Anorexia; Antiemetics; Antineoplastic Agents; Aprepitant; Asthenia; Constipati | 2007 |
Evaluation of outcomes in converting from intravenous ondansetron to oral granisetron: an observational study.
Topics: Administration, Oral; Adolescent; Adult; Antiemetics; Child; Constipation; Diarrhea; Drug Utilizatio | 2001 |